Suppr超能文献

解析载脂蛋白 E 基因型驱动的阿尔茨海默病不同脑区的蛋白质组学和脂质组学改变。

Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer's Disease Across Distinct Brain Regions.

机构信息

Department of Chemistry, North Carolina State University, Raleigh, North Carolina 27606, United States of America.

Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 99354, United States of America.

出版信息

J Proteome Res. 2024 Aug 2;23(8):2970-2985. doi: 10.1021/acs.jproteome.3c00604. Epub 2024 Jan 18.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disease with a complex etiology influenced by confounding factors such as genetic polymorphisms, age, sex, and race. Traditionally, AD research has not prioritized these influences, resulting in dramatically skewed cohorts such as three times the number of Apolipoprotein E (APOE) ε4-allele carriers in AD relative to healthy cohorts. Thus, the resulting molecular changes in AD have previously been complicated by the influence of apolipoprotein E disparities. To explore how apolipoprotein E polymorphism influences AD progression, 62 post-mortem patients consisting of 33 AD and 29 controls (Ctrl) were studied to balance the number of ε4-allele carriers and facilitate a molecular comparison of the apolipoprotein E genotype. Lipid and protein perturbations were assessed across AD diagnosed brains compared to Ctrl brains, ε4 allele carriers (APOE4+ for those carrying 1 or 2 ε4s and APOE4- for non-ε4 carriers), and differences in ε3ε3 and ε3ε4 Ctrl brains across two brain regions (frontal cortex (FCX) and cerebellum (CBM)). The region-specific influences of apolipoprotein E on AD mechanisms showcased mitochondrial dysfunction and cell proteostasis at the core of AD pathophysiology in the post-mortem brains, indicating these two processes may be influenced by genotypic differences and brain morphology.

摘要

阿尔茨海默病(AD)是一种神经退行性疾病,其病因复杂,受遗传多态性、年龄、性别和种族等混杂因素的影响。传统上,AD 研究并未优先考虑这些影响,导致队列严重偏倚,例如 AD 患者中载脂蛋白 E(APOE)ε4 等位基因的携带者数量是健康对照组的三倍。因此,AD 中先前的分子变化以前受到载脂蛋白 E 差异的影响。为了探索载脂蛋白 E 多态性如何影响 AD 的进展,研究了 62 名死后患者,其中 33 名患有 AD,29 名为对照组(Ctrl),以平衡 ε4 等位基因携带者的数量,并促进载脂蛋白 E 基因型的分子比较。与 Ctrl 大脑相比,评估了 AD 诊断大脑中的脂质和蛋白质扰动,ε4 等位基因携带者(携带 1 或 2 个 ε4s 的 APOE4+和非 ε4 携带者的 APOE4-),以及两个脑区(额叶皮层(FCX)和小脑(CBM))中 ε3ε3 和 ε3ε4 Ctrl 大脑之间的差异。载脂蛋白 E 对 AD 机制的区域特异性影响突出了线粒体功能障碍和细胞蛋白稳态是 AD 病理生理学的核心,表明这两个过程可能受基因型差异和脑形态的影响。

相似文献

1
Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer's Disease Across Distinct Brain Regions.
J Proteome Res. 2024 Aug 2;23(8):2970-2985. doi: 10.1021/acs.jproteome.3c00604. Epub 2024 Jan 18.
2
Vascular Dysfunction Is Central to Alzheimer's Disease Pathogenesis in APOE e4 Carriers.
Int J Mol Sci. 2022 Jun 26;23(13):7106. doi: 10.3390/ijms23137106.
4
Time Course and Severity of Cognitive Changes as a Function of Aβ Positivity and Genotype in Alzheimer Disease.
Neurology. 2025 Jul 22;105(2):e213853. doi: 10.1212/WNL.0000000000213853. Epub 2025 Jun 27.
6
The interactome of tau phosphorylated at T217 in Alzheimer's disease human brain tissue.
Acta Neuropathol. 2025 May 3;149(1):44. doi: 10.1007/s00401-025-02881-8.
7
Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease.
J Prev Alzheimers Dis. 2025 Apr;12(4):100065. doi: 10.1016/j.tjpad.2025.100065. Epub 2025 Jan 17.
8
Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer's Disease.
Clin Pharmacokinet. 2025 Mar;64(3):407-424. doi: 10.1007/s40262-025-01482-8. Epub 2025 Feb 5.
9
Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer's disease.
Acta Neuropathol Commun. 2024 Feb 9;12(1):25. doi: 10.1186/s40478-024-01731-0.
10
Neuropsychiatric symptoms and apolipoprotein E genotypes in neurocognitive disorders.
Neural Regen Res. 2025 Mar 25. doi: 10.4103/NRR.NRR-D-24-01274.

引用本文的文献

1
The evolution of analytical techniques for multiplex analysis of protein biomarkers.
Expert Rev Proteomics. 2025 Jul;22(7):255-272. doi: 10.1080/14789450.2025.2529185. Epub 2025 Jul 10.
2
Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3.
Alzheimers Dement. 2024 Jul;20(7):5044-5053. doi: 10.1002/alz.13848. Epub 2024 May 29.

本文引用的文献

1
APOE expression and secretion are modulated by mitochondrial dysfunction.
Elife. 2023 May 12;12:e85779. doi: 10.7554/eLife.85779.
2
Temporal and Sex-Linked Protein Expression Dynamics in a Familial Model of Alzheimer's Disease.
Mol Cell Proteomics. 2022 Sep;21(9):100280. doi: 10.1016/j.mcpro.2022.100280. Epub 2022 Aug 6.
3
Actin remodelling controls proteasome homeostasis upon stress.
Nat Cell Biol. 2022 Jul;24(7):1077-1087. doi: 10.1038/s41556-022-00938-4. Epub 2022 Jun 23.
4
Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology.
Alzheimers Dement (Amst). 2022 Feb 28;14(1):e12291. doi: 10.1002/dad2.12291. eCollection 2022.
6
Nucleotide biosynthesis links glutathione metabolism to ferroptosis sensitivity.
Life Sci Alliance. 2022 Jan 24;5(4). doi: 10.26508/lsa.202101157. Print 2022 Apr.
7
Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.
Lancet Public Health. 2022 Feb;7(2):e105-e125. doi: 10.1016/S2468-2667(21)00249-8. Epub 2022 Jan 6.
8
Microtubule-based transport is essential to distribute RNA and nascent protein in skeletal muscle.
Nat Commun. 2021 Oct 27;12(1):6079. doi: 10.1038/s41467-021-26383-9.
9
Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function.
Theranostics. 2021 Aug 17;11(18):8855-8873. doi: 10.7150/thno.59776. eCollection 2021.
10
Mitochondria in Neuronal Health: From Energy Metabolism to Parkinson's Disease.
Adv Biol (Weinh). 2021 Sep;5(9):e2100663. doi: 10.1002/adbi.202100663. Epub 2021 Aug 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验